The U.S. Food and Drug Administration (FDA) has approved LIB Therapeutics’ LEROCHOL (lerodalcibep-liga) for the treatment of adults with elevated low-density lipoprotein cholesterol (LDL-C)—marking a significant advancement in cardiovascular disease management and representing an important addition to the therapeutic options for patients who struggle to meet LDL-C targets with existing treatments. LEROCHOL, a novel, third-generation PCSK9 inhibitor developed by LIB Therapeutics, is designed t...